Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
POLY-PRED is an ophthalmic suspension approved in 1963 for treating inflammatory and allergic eye conditions. It is a small-molecule corticosteroid formulation delivered as topical eye drops. The mechanism involves local anti-inflammatory action to reduce ocular inflammation and associated symptoms.
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), indicating downsizing commercial infrastructure and shifting focus to managed care and retention strategies.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on POLY-PRED offers limited upside growth opportunity but provides deep experience in lifecycle management, generic defense, and mature product optimization within AbbVie's ophthalmic portfolio. This role is best suited for professionals seeking to build expertise in brand preservation, payer negotiations, and strategic product wind-down.
Worked on POLY-PRED at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.